Skip to content
- Bakacs T, Safadi R, Kovesdi I. (2018) Post-infection viral superinfection technology could treat HBV and HCV patients with unmet needs. Hepatology, Medicine and Policy; 3(1):2.
- Hornyak A, Lipinski KS, Bakonyi T, Forgach P, Horvath E, Farsang A et al. (2015) Effective multiple oral administration of reverse genetics engineered infectious bursal disease virus in mice in the presence of neutralizing antibodies. J Gene Med; 17(6-7):116-31.
- Bakacs, T., Schirrmacher, V., Moss, R.W. (2011) Oncolytic NDV therapy effective for years. Comment to Nature, 477:99-102 (#31286).
- Upadhyay, C., Ammayappan, A., Kovesdi, I. and Vakharia, V.N. (2011) A Recombinant Infectious Bursal Disease Virus expressing Foreign Epitopes. J. Virol. 85, 1408-1414.
- Mehrishi JN. and Bakács T. (2005) HIV and hepatitis G virus/GB virus C co-infection: beneficial or not? THE LANCET Infectious Diseases 5(8), 464-465.
- Bakacs, T., and Mehrishi, J. N. (2004). Examination of the value of treatment of decompensated viral hepatitis patients by intentionally coinfecting them with an apathogenic IBDV and using the lessons learnt to seriously consider treating patients infected with HIV using the apathogenic hepatitis G virus. Vaccine 23, 3-13.
- Bakacs T, Mehrishi JN. (2002) Intentional coinfection of patients with HCV infection using avian infection bursal disease virus. Hepatology 36(1):255.
- Csatary LK, Schnabel R, Bakacs T. (1999) Successful treatment of decompensated chronic viral hepatitis by bursal disease virus vaccine. Anticancer Res. 19:629-33.
- Csatary LK, Telegdy L, Gergely P, Bodey B, Bakacs T. (1998) Preliminary report of a controlled trial of MTH-68/B virus vaccine treatment in acute B and C hepatitis: a phase II study. Anticancer Res. 18:1279-82.